+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Therapeutic options for bacteremia caused by extended-spectrum beta-lactamase-producing Escherichia coli



Therapeutic options for bacteremia caused by extended-spectrum beta-lactamase-producing Escherichia coli



Clinical Infectious Diseases 51(1): 119-20; Author Reply 120-1




Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 056548571

Download citation: RISBibTeXText

PMID: 20518679

DOI: 10.1086/653446


Related references

Clinical outcomes and therapeutic options of bloodstream infections caused by extended-spectrum beta-lactamase-producing Escherichia coli. International Journal of Antimicrobial Agents 26(3): 254-257, 2005

Clinical Characteristics of Bacteremia Caused by Extended-spectrum Beta-lactamase-producing Escherichia coli at a Tertiary Hospital. Internal Medicine 56(14): 1807-1815, 2017

Therapeutic effectiveness of bacteriophages in the rescue of mice with extended spectrum beta-lactamase-producing Escherichia coli bacteremia. International Journal of Molecular Medicine 17(2): 347-355, 2006

Ertapenem in the treatment of bacteremia caused by extended-spectrum beta-lactamase-producing Escherichia coli: a propensity score analysis. International Journal of Infectious Diseases 16(1): E47-E52, 2012

Bacteremia caused by Escherichia coli producing extended-spectrum beta-lactamase: A case-control study of risk factors and outcomes. Scandinavian Journal of Infectious Diseases 34(8): 567-573, 2002

Oral treatment options for ambulatory patients with urinary tract infections caused by extended-spectrum-beta-lactamase-producing Escherichia coli. Antimicrobial Agents and ChemoTherapy 54(9): 4006-4008, 2010

Therapeutic effect of ceftazidime in a rabbit model of peritonitis caused by Escherichia coli producing CTX-M-14 extended-spectrum beta-lactamase. Zhonghua Jie He He Hu Xi Za Zhi 28(10): 689-693, 2005

Epidemiology and outcome of bacteremia caused by extended spectrum beta-lactamase (ESBL)-producing Escherichia coli and Klebsiella spp. in a tertiary care teaching hospital in south India. Journal of the Association of Physicians of India 58 Suppl: 13-17, 2010

Outcomes and risk factors for mortality in community-onset bacteremia caused by extended-spectrum beta-lactamase-producing Escherichia coli, with a special emphasis on antimicrobial therapy. Scandinavian Journal of Infectious Diseases 45(7): 519-525, 2013

Clinical characteristics and outcome of critically ill patients with bacteremia caused by extended-spectrum β-lactamase-producing and non-producing Escherichia coli. Journal of Infection and ChemoTherapy 24(11): 944-947, 2018

Bacteremia due to extended-spectrum beta -lactamase-producing Escherichia coli in the CTX-M era: a new clinical challenge. Clinical Infectious Diseases 43(11): 1407-1414, 2006

Bacteremia due to extended-spectrum beta-lactamase-producing Enterobacteriaceae other than Escherichia coli and Klebsiella. Journal of Microbiology, Immunology, and Infection 39(6): 496-502, 2006

Comparative assessment of inoculum effects on the antimicrobial activity of amoxycillin-clavulanate and piperacillin-tazobactam with extended-spectrum beta-lactamase-producing and extended-spectrum beta-lactamase-non-producing Escherichia coli isolates. Clinical Microbiology and Infection 16(2): 132-136, 2010

Outcome of cephalosporin treatment of bacteremia due to CTX-M-type extended-spectrum beta-lactamase-producing Escherichia coli. Diagnostic Microbiology and Infectious Disease 56(4): 351-357, 2006

Risk factors for bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli in a Turkish hospital. Journal of Infection in Developing Countries 7(7): 507-512, 2013